GleamWall
中文EN

PLX Protalix BioTherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%

Margins

Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%

Returns

ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$52.74M$53.40M
Cost of revenue$26.99M$24.32M
Gross profit$25.75M$29.08M
R&D expense$19.57M$12.97M
SG&A expense$11.68M$12.19M
Operating income-$5.50M$3.92M
Pretax income-$5.61M$4.15M
Income tax$996,000$1.22M
Net income-$6.60M$2.93M
EBITDA-$4.04M$5.22M
EPS (basic)-0.080.04
EPS (diluted)-0.080.04
Weighted avg. shares (diluted)78.55M81.06M
Balance sheet
Cash & equivalents$14.68M$19.76M
Receivables$8.84M$2.91M
Inventory$25.73M$21.24M
Current assets$66.67M$60.08M
PP&E, net$4.88M$4.59M
Total assets$82.35M$73.42M
Current liabilities$26.52M$25.62M
Total liabilities$34.12M$30.21M
Shareholders' equity$48.23M$43.21M
Shares outstanding80.43M75.85M
Cash flow statement
Operating cash flow-$11.99M$8.67M
Capital expenditure$1.64M$1.28M
Free cash flow-$13.63M$7.39M
Investing cash flow-$2.37M$4.22M
Financing cash flow$9.33M-$16.79M
Depreciation & amortization$1.47M$1.30M
Stock-based compensation$2.30M$3.25M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.